477 related articles for article (PubMed ID: 15585637)
1. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
2. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic studies to evaluate the enhanced antiproliferation of human keratinocytes by 1alpha,25-dihydroxyvitamin D(3)-3-bromoacetate, a covalent modifier of vitamin D receptor, compared to 1alpha,25-dihydroxyvitamin D(3).
Chen ML; Ray S; Swamy N; Holick MF; Ray R
Arch Biochem Biophys; 1999 Oct; 370(1):34-44. PubMed ID: 10496974
[TBL] [Abstract][Full Text] [Related]
4. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
5. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
Kim S; Shevde NK; Pike JW
J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
[TBL] [Abstract][Full Text] [Related]
6. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
Raval-Pandya M; Freedman LP; Li H; Christakos S
Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
Flanagan JN; Zheng S; Chiang KC; Kittaka A; Sakaki T; Nakabayashi S; Zhao X; Spanjaard RA; Persons KS; Mathieu JS; Holick MF; Chen TC
Anticancer Res; 2009 Sep; 29(9):3547-53. PubMed ID: 19667147
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE.
Sepulveda VA; Weigel NL; Falzon M
Steroids; 2006 Feb; 71(2):102-15. PubMed ID: 16243370
[TBL] [Abstract][Full Text] [Related]
11. Evidence for 1,25-dihydroxyvitamin D3-independent transactivation by the vitamin D receptor: uncoupling the receptor and ligand in keratinocytes.
Ellison TI; Eckert RL; MacDonald PN
J Biol Chem; 2007 Apr; 282(15):10953-62. PubMed ID: 17310066
[TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
14. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
[TBL] [Abstract][Full Text] [Related]
16. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
Zhao XY; Eccleshall TR; Krishnan AV; Gross C; Feldman D
Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
[TBL] [Abstract][Full Text] [Related]
17. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor.
Harant H; Spinner D; Reddy GS; Lindley IJ
J Cell Biochem; 2000 Apr; 78(1):112-20. PubMed ID: 10797570
[TBL] [Abstract][Full Text] [Related]
18. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
19. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D.
Young MV; Schwartz GG; Wang L; Jamieson DP; Whitlatch LW; Flanagan JN; Lokeshwar BL; Holick MF; Chen TC
Carcinogenesis; 2004 Jun; 25(6):967-71. PubMed ID: 14729578
[TBL] [Abstract][Full Text] [Related]
20. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer.
Chen TC; Wang L; Whitlatch LW; Flanagan JN; Holick MF
J Cell Biochem; 2003 Feb; 88(2):315-22. PubMed ID: 12520532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
